<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02536378</url>
  </required_header>
  <id_info>
    <org_study_id>SRM-2015-02</org_study_id>
    <nct_id>NCT02536378</nct_id>
  </id_info>
  <brief_title>POST-APPROVAL STUDY of TRANSCAROTID ARTERY REVASCULARIZATION in PATIENTS With SIGNIFICANT CAROTID ARTERY DISEASE</brief_title>
  <official_title>POST-APPROVAL STUDY of TRANSCAROTID ARTERY REVASCULARIZATION in PATIENTS With SIGNIFICANT CAROTID ARTERY DISEASE. The ROADSTER 2 Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Silk Road Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Silk Road Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ROADSTER 2 Study is intended to evaluate real world usage of the ENROUTE Transcarotid
      Stent when used with the ENROUTE Transcarotid Neuroprotection System by physicians of varying
      experience with the transcarotid technique.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 23, 2015</start_date>
  <completion_date type="Actual">April 29, 2019</completion_date>
  <primary_completion_date type="Actual">April 29, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>30 Days</target_duration>
  <primary_outcome>
    <measure>Rate of procedural success through 30 days following stent implant</measure>
    <time_frame>30 Days</time_frame>
  </primary_outcome>
  <enrollment type="Actual">692</enrollment>
  <condition>Carotid Artery Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with atherosclerotic extracranial internal carotid stenosis (ICA) with or without
        involvement of the contiguous common artery (CCA) determined by duplex ultrasound, CT/CTA,
        MR/MRA or angiography to be:

          -  Symptomatic: greater than or equal to 50% stenosis or

          -  Asymptomatic: greater than or equal to 80% stenosis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          1. Patient must meet one of the following criteria regarding neurological symptom status
             and degree of stenosis:

             Symptomatic: Stenosis must be &gt;50% as determined by an angiogram and the patient has a
             history of stroke (minor or non-disabling; NIHSS ≤4 or mRS ≤2), TIA and/or amaurosis
             fugax within 180 days of the procedure procedure ipsilateral to the carotid artery to
             be stented.

             OR Asymptomatic: Stenosis must be &gt;80% as determined by angiogram without any
             neurological symptoms within the prior 180 days.

          2. Target vessel must meet all requirements for ENROUTE Transcarotid Neuroprotection
             System and ENROUTE Stent System (refer to IFU for requirements).

          3. Patient has a discrete lesion located in the internal carotid artery (ICA) with or
             without involvement of the contiguous common carotid artery (CCA).

          4. Patient is ≥18 years of age.

          5. Patient understands the nature of the procedure and has provided a signed informed
             consent using a form that has been reviewed and approved by the Institutional Review
             Board/Ethics Committee of the respective clinical site prior to the procedure. This
             will be obtained prior to participation in the study.

          6. Patient is willing to comply with the protocol requirements and return to the
             treatment center for all required clinical evaluations.

          7. Patient must have a life expectancy ≥ 3 years at the time of the index procedure
             without contingencies related to other medical, surgical or endovascular intervention.

          8. Patient meets at least one of the surgical high-risk criteria listed below.

        Anatomic High Risk Inclusion Criteria:

        A. Contralateral carotid artery occlusion B. Tandem stenoses &gt;70% C. High cervical carotid
        artery stenosis D. Restenosis after carotid endarterectomy E. Bilateral carotid artery
        stenosis requiring treatment within 30 days after index treatment.

        F. Hostile Necks which the Investigator deems safe for transcarotid access including but
        not limited to:

        I. Prior neck irradiation II. Radical neck dissection III. Cervical spine immobility

        Clinical High Risk Inclusion Criteria:

        G. Patient is &gt; 75 years of age H. Patient has &gt; 2-vessel coronary artery disease and
        history of angina of any severity I. Patient has a history of angina

          -  Canadian Cardiovascular Society (CCS) angina class 3 or 4 or

          -  unstable angina

        J. Patient has congestive heart failure (CHF) - New York Heart Association (NYHA)

          -  Functional Class III or IV

        K. Patient has known severe left ventricular dysfunction

          -  LVEF &lt;30%.

        L. Patient has had a myocardial infarction &gt; 72 hours and &lt; 6 weeks prior to procedure.

        M. Patient has severe pulmonary disease (COPD) with either:

          -  FEV1 &lt;50% predicted or

          -  chronic oxygen therapy or

          -  resting PO2 of &lt;60 mmHg (room air)

        N. Patient has permanent contralateral cranial nerve injury O. Patient has chronic renal
        insufficiency (serum creatinine &gt; 2.5 mg/dL).

        REMINDER: The following is a list of anatomical considerations that are not suitable for
        transfemoral CAS with distal protection that are NOT contraindications for enrollment in
        the ROADSTER 2 Study including but not limited to:

        I. TypeII, III, or Bovine arch II. Arch atheroma or calcification III. Atheroma of the
        great vessel origins IV. Tortuous distal ICA V. Tortuous or occluded iliofemoral segments
        VI. Occluded aortoiliac segments

        EXCLUSION CRITERIA:

        Each potential patient must be screened to ensure that they do not meet any of the
        following exclusion criteria. This screening is to be based on known medical history and
        data available at the time of eligibility determination and enrollment.

          1. Patient has an alternative source of cerebral embolus, including but not limited to:

               1. Patient has chronic atrial fibrillation.

               2. Patient has had any episode of paroxysmal atrial fibrillation within the past 6
                  months, or history of paroxysmal atrial fibrillation requiring chronic
                  anticoagulation.

               3. Knowledge of cardiac sources of emboli. e.g. left ventricular aneurysm,
                  intracardiac filling defect, cardiomyopathy, aortic or mitral prosthetic heart
                  valve, calcific aortic stenosis, endocarditis, mitral stenosis, atrial septal
                  defect, atrial septal aneurysm, or left atrial myxoma).

               4. Recently (&lt;60 days) implanted heart valve (either surgically or endovascularly),
                  which is a known source of emboli as confirmed on echocardiogram.

               5. Abnormal angiographic findings: ipsilateral intracranial or extracranial arterial
                  stenosis (as determined by angiography or CTA/MRA ≤ 6 months prior to index
                  procedure) greater in severity than the lesion to be treated, cerebral aneurysm &gt;
                  5 mm, AVM (arteriovenous malformation) of the cerebral vasculature, or other
                  abnormal angiographic findings.

          2. Patient has a history of spontaneous intracranial hemorrhage within the past 12
             months, or has had a recent (&lt;7 days) stroke of sufficient size (on CT or MRI) to
             place him or her at risk of hemorrhagic conversion during the procedure.

          3. Patient had hemorrhagic transformation of an ischemic stroke within the past 60 days.

          4. Patient with a history of major stroke attributable to either carotid artery (CVA or
             retinal embolus) with major neurological deficit (NIHSS ≥ 5 OR mRS ≥ 3) likely to
             confound study endpoints within 1 month of index procedure.

          5. Patient has an intracranial tumor.

          6. Patient has an evolving stroke.

          7. Patient has neurologic illnesses within the past two years characterized by fleeting
             or fixed neurologic deficit which cannot be distinguished from TIA or stroke,
             including but not limited to: moderate to severe dementia, partial or secondarily
             generalized seizures, complicated or classic migraine, tumor or other space-occupying
             brain lesions, subdural hematoma, cerebral contusion or other post-traumatic lesions,
             intracranial infection, demyelinating disease, or intracranial hemorrhage).

          8. Patient has had a TIA or amaurosis fugax within 48 hrs prior to the procedure.

          9. Patient has an isolated hemisphere.

         10. Patient had or will have CABG, endovascular stent procedure, valve intervention or
             vascular surgery within 30 days before or after the intervention.

         11. Myocardial Infarction within 72 hours prior to the intervention.

         12. Presence of a previous placed intravascular stent in target vessel or ipsilateral CCA
             or significant CCA inflow lesion.

         13. Occlusion or [Thrombolysis In Myocardial Infarction Trial (TIMI 0)] &quot;string sign&quot; &gt;1cm
             of the ipsilateral common or internal carotid artery.

         14. An intraluminal filling defect (defined as an endoluminal lucency surrounded by
             contrast, seen in multiple angiographic projections, in the absence of angiographic
             evidence of calcification) whether or not it is associated with an ulcerated target
             lesion.

         15. Ostium of Common Carotid Artery (CCA) requires revascularization.

         16. Patient has an open stoma in the neck.

         17. Female patients who are pregnant or may become pregnant.

         18. Patient has history of intolerance or allergic reaction to any of the study
             medications or stent materials (refer to stent IFU), including aspirin (ASA),
             ticlopidine, clopidogrel, statin or contrast media (that can't be pre medicated).
             Patients must be able to tolerate statins and a combination of ASA and ticlopidine or
             ASA and clopidogrel.

         19. Patient must have a life expectancy &lt;3 years without contingencies related to other
             medical, surgical, or interventional procedures as per the Wallaert Score and patients
             with primary, recurrent or metastatic malignancy who do not have independent
             assessment of life expectancy performed by the treating oncologist or an appropriate
             specialist other than the physician performing TCAR.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vikram Kashyap, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Case Medical Center Harrington Heart &amp; Vascular Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Schneider, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaiser Permanente, Hawaii</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peter Morton UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Healthcare</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente, Hawaii</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Health Methodist Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unity Point Health - Iowa Clinic</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Health Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Maine Medical Center</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elizabeth's Medical Center</name>
      <address>
        <city>Brighton</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Vascular Center</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abbott Northwestern</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Ct.</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sisters of Charity Hospital</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Your Presbytarian - Weill Cornell</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook Medicine</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina, Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Case Medical Center and Case Western Reserve University School of Medicine</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Heart</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's University Health Network</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC (University of Pittsburgh Medical Center)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Hospital System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellmont CVA Heart Institute</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiothoracic and Vascular Surgeons</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist DeBakey Heart &amp; Vascular Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michael E DeBakey VA Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott and White Memorial Hospital</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Vascular Specialists</name>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <zip>23320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAMC Clinical Trials Center</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Technical University Munich</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Quirónsalud Marbella</name>
      <address>
        <city>Marbella</city>
        <zip>29603</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/28335706</url>
    <description>Transcarotid Artery Revascularization With Flow Reversal: The PROOF Study</description>
  </link>
  <results_reference>
    <citation>Alpaslan A, Wintermark M, Pintér L, Macdonald S, Ruedy R, Kolvenbach R. Transcarotid Artery Revascularization With Flow Reversal. J Endovasc Ther. 2017 Apr;24(2):265-270. doi: 10.1177/1526602817693607. Epub 2017 Feb 17.</citation>
    <PMID>28335706</PMID>
  </results_reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>August 27, 2015</study_first_submitted>
  <study_first_submitted_qc>August 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2015</study_first_posted>
  <last_update_submitted>May 7, 2019</last_update_submitted>
  <last_update_submitted_qc>May 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carotid Artery Diseases</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>June 22, 2020</submitted>
    <submission_canceled>June 23, 2020</submission_canceled>
    <submitted>June 23, 2020</submitted>
    <returned>July 9, 2020</returned>
    <submitted>July 9, 2020</submitted>
    <returned>July 24, 2020</returned>
    <submitted>July 27, 2020</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

